Aegle Therapeutics Corp (PRIVATE:AEGLE)

Aegle Therapeutics Corp (PRIVATE:AEGLE)

Share Price
0 (0 %)
Market Cap
$0.00 m
Proactive Investors - Run By Investors For Investors

Aegle Therapeutics Corp

Aegle Therapeutics CEO Shelley Hartman joined Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. 

The Phase 1/2a ready company isolating extracellular vesicles from allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions, including burns and epidermolysis bullosa, a rare pediatric connective tissue disorder, and to prevent...

Sector: Pharma & Biotech
col 3
col 4
col 5
col 6

Aegle Therapeutics Corp Timeline


© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use